Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Levosimendan.

D P Figgitt1, P S Gillies, K L Goa

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|May 23, 2001
PubMed
Summary
This summary is machine-generated.

Levosimendan, an intravenous treatment for cardiac failure, enhances heart contractility without increasing oxygen demand. It improves cardiac output and reduces mortality in decompensated heart failure patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs·2013
Same author

Adjuvanted influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Liposomal influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Follitropin alpha in infertility: a review.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Levosimendan is a pyridazinone-dinitrile derivative.
  • It acts as a calcium sensitizer and affects ATP-sensitive potassium channels.

Purpose of the Study:

  • To evaluate the efficacy and safety of intravenous levosimendan in treating decompensated cardiac failure.
  • To assess its effects on cardiac contractility, oxygen demand, and hemodynamic parameters.

Main Methods:

  • Intravenous administration of levosimendan.
  • Large, double-blind, randomized trials in patients with decompensated congestive heart failure (CHF).
  • Smaller trials in patients after cardiac surgery.

Main Results:

  • Levosimendan enhanced contractility without increasing myocardial oxygen demand.

Related Experiment Videos

  • It demonstrated antistunning effects and caused vasodilation.
  • IV levosimendan significantly reduced worsening CHF or death and improved cardiac output, decreasing filling pressures.
  • Common adverse events included headache, hypotension, and nausea, primarily due to vasodilation.

    • Conclusions:

    • Levosimendan is an effective and well-tolerated treatment for decompensated cardiac failure.
    • It improves hemodynamic function and reduces adverse outcomes in CHF patients.
    • No clinically significant pharmacokinetic interactions were observed with common co-administered drugs.